[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"depression---major-depressive-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:depression---major-depressive-disorder":652},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,113,0,25,[9,56,86,108,133,154,180,211,239,264,290,307,332,358,375,399,420,456,485,505,526,550,572,601,628],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100577061",false,"NCT06793397","A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder","An Efficacy and Safety, Phase III, Multi-center, Double-Blind, Randomized Controlled Study Comparing 2 Active Doses of CYB003 and Placebo in Eligible Participants With Major Depressive Disorder","EMBRACE","Inclusion Criteria:\n\nParticipants must meet all the following criteria to be included in the trial:\n\n* Age18 to 85 years.\n* Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR \\[if single episode, duration of ≥4 weeks and ≤24 months\\] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60.\n* Moderate to severe depression at Screening and Baseline, independently confirmed.\n* Participants have been on a stable dose of antidepressant medication (label specified) at an adequate dose in the last 4 weeks prior to Screening and has had an inadequate response (less than 50% improvement), as judged by the Investigator.\n* Participant has a body mass index (BMI) of 40 kg\u002Fm2 or less (BMI ≤40 kg\u002Fm2), inclusive, at Screening.\n* Participant is able to refrain from nicotine use during the dosing session (up to 8 hours).\n* Participants capable of producing sperm must use a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person of childbearing potential.\n* Participants of childbearing potential who have a partner capable of producing sperm must agree to use a highly effective method of contraception in combination with the use of a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication. Such participants must have a negative pregnancy test at Screening and Day 1 prior to dosing.\n* Participants of non-childbearing potential who are or were capable of producing eggs (ova) must have been postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.\n* Participants have provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.\n\nExclusion Criteria\n\nParticipants with any of the following characteristics\u002Fconditions will be excluded from trial participation:\n\n* Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder, brief psychotic disorder, current or previous history of bipolar disorder, or current borderline personality disorder.\n* Participants with a medical diagnosis of attention deficit hyperactivity disorder (ADHD) will be excluded if currently taking medication for ADHD.\n* Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first-degree relatives).\n* Significant suicide risk within the past 6 months, during the Screening Period, or at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c) clinical assessment of significant suicidal risk during clinical interview; or (d) non-suicidal self-injury within 12 months of Screening.\n* Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments of 2 different classes given at an adequate dose (label specified) for an adequate duration as judged by the Investigator and clinical interview.\n* Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.\n* Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressants, mirtazapine, trazodone, moclobemide, buspirone, or an antipsychotic or mood stabilizer. Note: if receiving these medications are for another indication, they must be discontinued ≥ 14 days or 5 half-lives, whichever is longer, prior to Day 1.\n* Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 10 times over the participant's lifetime or any psychedelic use within 12 months prior to Screening.\n* Participant report of (or if available in medical record) treatment with ketamine or S-ketamine use within 6 months prior to Screening.\n* Clinically relevant history of abnormal physical health interfering with the trial (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal \\[including dyspepsia or gastroesophageal reflux disease\\], hepatic, or renal disorder).\n* Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication.\n* Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate.\n* Participants have a presence or relevant history of organic brain disorders.\n* Participant is taking or has taken OTC doses of 5-HTP or St John's Wort within prior to trial medication administration.\n* Donation of blood or plasma within 4 weeks prior to first dosing and until 4 weeks after final dosing.\n* Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing.\n* Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing.\n* History of serotonin syndrome.\n* Unwilling to consent to audio and video recording of psychological support and dosing sessions.","ALL","18 Years","85 Years",{"count":21,"type":22},330,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.\n\nFor more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https:\u002F\u002Fembrace-mdd-trial.com\u002F",[28,29,30,31,32,33],"Major Depressive Disorder (MDD)","Depression in Adults","Depression - Major Depressive Disorder","Depression Disorders","Depression Disorder","Depression",[35,36,33,37,38,39,40,41,42],"MDD","Psychedelic","Major Depressive Disorder","CYB003","CYB003-001","CYB003-002","Psilocybin","psilocin-7438","RECRUITING","2026-06-29",{"date":46,"type":47},"2026-06-30","ACTUAL",{"date":49,"type":47},"2025-12-10",{"date":51,"type":22},"2027-05-08",{"name":53,"class":54},"Cybin IRL Limited","INDUSTRY",68,{"id":57,"slug":4,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":85},"100642930","NCT07639606","Mobile Cognitive Behavioral Therapy in Early Stroke Recovery","Inclusion Criteria:\n\n* Age 18-79\n* Positive screen on the Hospital Anxiety and Depression Scale (HADS), either the HADSD (depression, score \\>= 8) and\u002For HADS-A (anxiety, score \\>= 8).\n* Stroke that occurred within 1 month prior to study initiation.\n* Capacity to provide consent as determined by the UCSD Brief Assessment for Capacity to Consent (UBACC)\n* Montreal Cognitive Assessment (MoCA) score greater than or equal to 18, indicating no more than mild cognitive difficulties\n* Ability to use iPhone or iPad independently or through the assistance of a caregiver (participants will use their own iPhone if they have one, otherwise they will be loaned an iPad by the study team)\n* Able to adhere to all study requirements and willingness to participate in the full study duration\n\nExclusion Criteria:\n\n* Aphasia or neglect that would interfere with use of the app, as determined through evaluation by speech-language pathology and occupational therapy conducted as part of standard clinical care\n* Non-fluency in English\n* History of a major neurologic disorder or of serious mental illness (bipolar or psychotic disorder, alcohol or substance use disorder as assessed through chart review)\n* Active suicidal ideation requiring a higher level of care\n* Severe depression and\u002For anxiety based on the initial evaluation and clinical judgment of the PI, which warrants a higher level of care and\u002For immediate referral to psychiatric services\n* Any other clinical or medical reason in the initial evaluation that suggests the study is not appropriate for the participant","79 Years",{"count":63,"type":22},10,[65],"NA","This study aims to pilot \"Maya,\" a mobile cognitive behavioral therapy app, for use in adults with stroke experiencing depression and\u002For anxiety. This study will assess the acceptability, feasibility, and preliminary efficacy of Maya within the acute rehabilitation period.",[68,69,30],"Anxiety","Stroke",[71,72,73,74],"stroke recovery","stroke rehabilitation","cognitive behavioral therapy","CBT","NOT_YET_RECRUITING","2026-06-26",{"date":46,"type":47},{"date":79,"type":22},"2026-07",{"date":81,"type":22},"2029-03",{"name":83,"class":84},"Weill Medical College of Cornell University","OTHER",1,{"id":87,"slug":4,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":97,"conditions":98,"keywords":99,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":85},"100604001","NCT07143838","Enhancing Slow Wave Sleep in Depression","Investigating Slow Wave Sleep Enhancement to Improve Cognitive Function in Adults With Depression","Inclusion Criteria:\n\n* Ability to complete overnight sleep study including placement of EEG leads\n* Ability to read and understand English.\n* Moderate depression\n* Self-reported cognitive complaints\n\nExclusion Criteria:\n\n* Previous adverse reaction to transcranial electrical stimulation\n* Presence of implanted devices (e.g. intracranial device, cochlear implant)\n* Presence of metal in head (e.g. surgical clip)\n* Sensitivity or allergy to silver\n* Presence of significant neurologic disease (e.g. Parkinson's disease, epilepsy\u002Fseizure disorder, severe migraine disorder)\n* History of significant head trauma\n* History of stroke or other ischemic event\n* Diagnosed with schizophrenia, bipolar disorder, substance use disorder, or presence of current suicidal ideation\n* Currently taking medications that could alter EEG or cognitive function\n* Presence of severe insomnia\n* Presence of severe, untreated sleep apnea\n* Currently pregnant\n* Planned travel outside time zone during the study","40 Years","80 Years",{"count":95,"type":22},12,[65],"The goal of this pilot study is to determine if non-invasive brain stimulation during sleep can increase deep sleep in adults with depression. It will also determine if increased deep sleep improves cognitive performance and mood ratings. Participants will be asked to wear a non-invasive device that records their brain activity and delivers transcranial electrical stimulation during sleep. Participants will also wear an actigraphy watch that measures activity levels throughout the study. In addition, participants will complete several cognitive assessments and mood and sleep questionnaires throughout the study.",[30],[100,33],"Sleep",{"date":44,"type":47},{"date":103,"type":47},"2026-06-04",{"date":105,"type":22},"2027-03",{"name":107,"class":84},"Wake Forest University Health Sciences",{"id":109,"slug":4,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":118,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":130,"leadSponsor":132,"locationsCount":85},"100645335","NCT07680140","Biomarker-Guided Antidepressant Selection","Biomarker-Guided Antidepressant Selection for Treatment-Resistant Depression","BioSelect","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Adults of all genders aged 18-70 at the time of screening\n3. Diagnosis of Major Depressive Disorder (by DSM-5 criteria)\n4. Depressive symptoms of at least moderate severity (GRID HDRS-17 score \\>= 14 or as determined by a study clinician)\n5. Failed at least 1 prior trial of standard first-line treatment for MDD per the modified Antidepressant Treatment History form, the Maudsley Staging Method, and APA Practice Guidelines (e.g., SSRI, SNRI, CBT) OR initiated and discontinued a trial of a first-line treatment for MDD (e.g. could not tolerate side effects, etc.)\n6. Not currently taking antidepressants OR on a stable dose of antidepressant for at least 1month prior to screening and plans to remain off antidepressants OR on this stable dose for the duration of participation\n7. Current medication regimen is compatible with safe participation in the trial in the assessment of a study clinician\n8. Access to psychiatric care before, during, and after completion of the study\n9. For females of reproductive potential: agreement to use effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation\n10. Proficiency in English sufficient to complete assessments and follow study procedure instructions\n11. Stated willingness to comply with all study procedures and availability for the duration of the study\n\nExclusion Criteria:\n\n1. Imminent risk of suicide\n2. Presence of primary psychiatric diagnosis other than MDD (e.g., post-traumatic stress disorder, obsessive-compulsive disorder, MDD with psychotic features, primary psychotic illness, bipolar I or II disorder)\n3. History of epilepsy or a history of seizures that would influence the participant's risk for TMS-evoked seizures; history of any condition \u002F concurrent medication that could notably lower seizure threshold in the estimation of a study clinician\n4. Met criteria for any clinically significant substance use disorder (by DSM-V criteria) with active substance misuse in the 6 months prior to screening\n5. Lifetime history of PCP\u002Fketamine abuse\n6. History or presence of significant neurological disorder that may be contributing to current depressive symptoms in the judgment of a study clinician (e.g., traumatic brain injury, stroke, Parkinson's disease or other movement disorder, epilepsy)\n7. Presence of medical contraindications to ketamine, including liver function tests \\> 2.5x normal limit, recent myocardial infarction, congestive heart failure \\> stage 2, angina pectoris, clinically significant bradycardia or tachycardia at the baseline assessment, or uncontrolled hypertension\n8. MRI contraindication, including presence of ferromagnetic foreign metal bodies or implants, implanted or conductive ferromagnetic objects in or near the head (e.g., stents, deep brain stimulators, vagus nerve stimulators, aneurysm coils, ocular implants, cochlear implants), and ferromagnetic permanent make-up that may undergo heating in an MRI scanner\n9. Individuals who are nursing, pregnant, or contemplating pregnancy within the length of study participation\n10. Abnormal bloodwork that may be contributing to depressive symptoms in the estimation of a study clinician (e.g. indicators of clinically significant hypothyroidism, kidney failure, liver failure, etc.)\n11. History or presence of any disorder or medical condition that, in the opinion of the study team, may compromise, interfere, or limit the individual's ability to complete the intervention or study procedures","70 Years",{"count":117,"type":22},27,[119],"PHASE4","Depression is one of the leading causes of disability worldwide. Common treatments like antidepressant medications and talk therapy work well for some people, but many others do not improve, even after trying multiple treatments.\n\nThis study will investigate two alternative treatment options for people whose depression has not responded to standard treatments: repetitive transcranial magnetic stimulation (rTMS), a non-invasive form of brain stimulation, and ketamine, a fast-acting medication. It can be difficult to decide between these interventions in clinical practice, and selecting between them often comes down to patient preference and trial and error. This study is working to optimize the selection approach: using biological and behavioral markers to match each person to identify biomarkers that may predict response to rTMS or ketamine. Investigators believe that differences in how individuals respond to rTMS versus ketamine are partly explained by differences in how their brains are organized, and that these differences can be measured and used to guide intervention decisions. This is an early-stage pilot study designed to test whether this biomarker-based approach is practical and acceptable to patients. Investigators will evaluate how well a combination of brain imaging and clinical data can predict, at the individual level, who is likely to respond to rTMS versus ketamine. The ultimate goal is to develop a reliable, scalable tool that helps clinicians make faster and more informed intervention decisions, reducing the time people with treatment-resistant depression spend searching for an antidepressant that works.",[30,122,123,124,125],"Treatment-resistant Depression (TRD)","rTMS","Ketamine","fMRI","2026-06-25",{"date":128,"type":47},"2026-07-02",{"date":79,"type":22},{"date":131,"type":22},"2028-12",{"name":83,"class":84},{"id":134,"slug":4,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":139,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":23,"phases":142,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":151,"leadSponsor":153,"locationsCount":85},"100635490","NCT07553364","Auditory Stimulation for Insomnia and Depression","Feasibility of Using Alpha Phase-Locked Auditory Stimulation for Insomnia Symptoms in People With Depression","Inclusion Criteria:\n\n* Ability to complete overnight EEG study including placement of EEG leads\n* Ability to read and understand English\n* Presence of Insomnia\n* Moderate Depression\n* Home internet and smartphone (Android or Apple) device access\n\nExclusion Criteria:\n\n* Presence of severe, untreated sleep apnea\n* Presence of restless leg syndrome\n* Significant neurological disease (e.g. Parkinson's disease, epilepsy)\n* Diagnosed with schizophrenia, bipolar disorder, substance use disorder, or presence of current suicidal ideation\n* Has active implanted device ( e.g. intracranial device, cochlear implant)\n* Currently deaf or experiencing hearing loss or using hearing aids\n* Currently taking medications that could alter EEG\n* Currently pregnant","20 Years","50 Years",{"count":7,"type":22},[65],"The goal of this clinical trial is to determine if alpha phase-locked auditory stimulation can improve sleep in people with insomnia and depression. The main goals of the pilot study are the following:\n\nDetermine whether alpha phase-locked auditory stimulation (active stimulation) improves objective and subjective sleep in individuals with insomnia and depression.\n\nThe study team hypothesizes that active auditory stimulation will reduce objective and subjective sleep onset latency (SL) and wake after sleep onset (WASO) compared to a sham stimulation.\n\nParticipants will:\n\n* Wear Elemind Neuromod headband nightly for 4 weeks (1 week baseline, 1 week active\u002Fsham stimulation, 1 week washout, and 1 week opposite condition - active\u002Fsham stimulation)\n* Wear actigraphy watch for duration of the study\n* Complete questionnaires regarding their sleep, mood, and satisfaction with the device",[30,145],"Insomnia",[147,33,145],"sleep","2026-06-24",{"date":76,"type":47},{"date":79,"type":22},{"date":152,"type":22},"2027-12-01",{"name":107,"class":84},{"id":155,"slug":4,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":160,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":85},"100601009","NCT07104916","Mindfulness-based Psilocybin Therapy for PTSD","A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD)","Inclusion Criteria\n\nParticipants meeting the following criteria will be included in the study:\n\n1. Participant is assigned female or male at birth.\n2. Participant is aged between 21 to 65 years, inclusive, at Screening. This is to reduce variability in brain function and connectivity in this small pilot study that may be related to age \u002F developmental factors in persons under 21 and over 65.\n3. Participant has a BMI of 18 to 30 kg\u002Fm2, inclusive, at Screening.\n4. Participant has a diagnosis of PTSD (as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition \\[DSM-5\\] established through a clinician interview that includes the Mini-International Neuropsychiatric Interview \\[MINI\\]) and the Clinician Administered PTSD Scale for DSM-5 (CAPS-5).\n5. PTSD severity moderate to severe based on CAPS-5 score ≥25, and with moderate depression MADRS ≥20.\n6. Participants capable of producing sperm must use a condom during the trial and for 3 months after their dose of trial medication, if their partner is a person of childbearing potential. In addition, their partner of childbearing potential must also use a highly effective method of contraception (i.e., failure rate less than 1% when used consistently and correctly) from dosing until 3 months following dosing. Condoms alone and abstinence are not considered highly effective methods of contraception.\n7. Participants of childbearing potential must agree to use a highly effective method of contraception (i.e., failure rate less than 1% when used consistently and correctly) in combination with use of a condom by a partner who is capable of producing sperm, during the trial and for 3 months after dosing. Condoms alone and abstinence are not considered highly effective methods of contraception. Such participants must have a negative pregnancy test at Screening and Day 1.\n8. Participants of non-childbearing potential who are or were capable of producing eggs (ova) must be postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy or bilateral oophorectomy. Postmenopausal is defined as spontaneous amenorrhea for at least 12 months, and a serum follicle stimulating hormone (FSH) level in the menopausal range, unless the participant is taking hormone replacement therapy or is using hormonal contraception.\n9. Provision of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.\n\nIf appropriate, describe why certain populations may be excluded (e.g., non-English speaking individuals for studies involving informed consent).\n\nExclusion Criteria\n\nParticipants with the following will be excluded from study participation:\n\n1. Cardiovascular disease, including coronary artery disease (CAD) and congestive heart failure (CHF). This is an FDA requirement.\n2. Current or previously diagnosis of schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder or brief psychotic disorder; current or previous history of bipolar disorder, or current personality disorder (as determined by MINI at Screening). This is an FDA requirement.\n3. Clinically significant risk of suicidality, as determined through a comprehensive psychiatric interview that incorporates the Columbia Suicide Severity Rating Scale (CSSRS); a score of 4 or higher on the suicidal ideation subscale of C-SSRS (past 6 months) or any suicidal behaviour (lifetime), would be exclusionary.\n4. History of substance use disorder within the 12 months, as assessed by a structured clinical interview (Mini International Neuropsychiatric Interview \\[MINI\\], Version 7.0.2) or determined by self-report, or intake of \\>21 units of alcohol weekly, and the inability to refrain from alcohol use from 48 hours before Screening and each scheduled visit until discharge from the study site. One unit is equivalent to a 285 mL glass of full-strength beer or 1 (30 mL) measure of spirits or 1 glass (100 mL) of wine.\n5. Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressant, other non-SSRI or non-SNRI antidepressants (e.g. bupropion, mirtazapine, etc), an antipsychotic or a mood stabilizer.\n6. Exposure to psilocybin, or any other psychedelics, such as ayahuasca, mescaline, LSD or peyote more than 10 times in the last 10 years, or any psychedelic use within 6 months prior to Screening.\n7. Use of psychotropic medicine\u002Fsupplement (or medicine\u002Fsupplement that would interact with psilocybin) including buspirone and venlafaxine, during the 28 days before dosing. Participants may take a stable chronic dose of other SSRI antidepressant medication(s) and\u002For sedatives\u002Fhypnotics. The Investigator and study team may review medication on a case-by-case basis to determine if its use would compromise participant safety or interfere with study procedures or data interpretation.\n8. Family history of schizophrenia or schizoaffective disorder (first degree relatives), or bipolar disorder type 1 (first degree relatives).\n9. Clinically relevant history of abnormal physical health interfering with the study as determined by medical history and physical examinations obtained during Screening as judged by the Investigator (including \\[but not limited to\\], neurological, endocrine, cardiovascular, respiratory, gastrointestinal (including dyspepsia or gastroesophageal reflux disease), hepatic, or renal disorder).\n10. Participant has a presence or relevant history of any of the following medical conditions: organic brain disorders (e.g., epilepsy, seizure, intracranial hypertension, intracranial bleed and aneurysmal disease, brain tumor or other medical conditions associated with seizures or convulsions).\n11. Diagnosis of hypertension or arrhythmia.\n12. Clinically relevant abnormal heart rate (resting supine heart rate \\>100 bpm) or blood pressure (resting supine systolic blood pressure (SBP) above 140 mmHg or diastolic blood pressure (DBP) above 90 mmHg) at screening. Screening supine SBP, DBP and heart rate for evaluation will be the average of 3 readings obtained after at least 5 minutes rest. Participants with abnormal vital signs which are out of range and deemed clinically significant by the Investigator at Day 1, following triplicate readings.\n13. Presence of clinically significant ECG abnormalities at the Screening visit, as defined by medical judgement.\n14. QT interval corrected for heart rate using Fridericia's formula (QTcF) \\>450 msec at Screening, following triplicate ECG readings.\n15. Hypothyroidism and\u002For current abnormal thyroid function tests. In case of uncertain or questionable screening thyroid function test results, the TSH test may be repeated once during screening. The TSH test must be reviewed to ensure that it is within normal limits before randomizing a participant into the study.\n16. Clinically relevant abnormal laboratory results (including hepatic and renal panels, complete blood count, chemistry panel and urinalysis), 12-lead ECG and vital signs, or physical findings at Screening. In case of uncertain or questionable results, tests performed during Screening may be repeated once to confirm eligibility or judged to be clinically irrelevant.\n17. Other eligibility considerations (i.e., participant personal circumstances, behavior, and\u002For any current problem that might interfere with participation or that is incompatible with establishment of rapport or safe exposure to psilocin), as judged by the Investigator.\n18. History or clinical evidence of any disease and\u002For existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion (ADME) of the study drug.\n19. Any other concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study as outlined in this Protocol, or that would, in the opinion of the Investigator, pose an unacceptable risk to the participant in this study.\n20. Participant is not fluent in English. Participants must be fluent in English because the consent form as well as all assessments are written and will be administered\u002Fcommunicated in English.\n21. Aspartate aminotransferase (AST), alanine transaminase (ALT), gamma-glutamyl transferase (GGT) or total bilirubin levels ≥1.5 x the upper limit of normal (ULN) at Screening. These laboratory evaluations may be repeated once at the discretion of the Investigator. If the repeat test is within the reference range, the participant may be included if the Investigator considers that the previous finding will not introduce additional risk factors.\n22. Positive urine test for drugs of abuse or alcohol breath test at Screening or Day 1. A positive test for cannabinoids (e.g., marijuana) at Screening may not exclude a participant if after discussion with and evaluation by the Investigator, the participant agrees not to use any marijuana or other cannabinoid products during the study, and if allowed to participate, the participant must test negative for cannabinoids on Day 1.\n23. Participant who consumes excessive amounts of caffeine (e.g., coffee, tea, caffeinated sodas) or (methyl) xanthines (e.g., chocolate) based on the Investigator's determination and discretion.\n24. The participant has participated in a clinical study and has received a medication or a new chemical entity within 3 months prior to dosing of current study medication.\n25. Known sensitivity to psilocybin, psilocin and\u002For any excipients present in the formulation.\n26. Participant is taking or has taken any drugs known to inhibit monoamine oxidase within 28 days prior to study drug administration.\n27. Participant is taking or has taken OTC doses of 5-hydroxytryptophan or St John's Wort within 28 days prior to study drug administration.\n28. Strenuous exercise within 48 hours prior to each visit, and while at the study site.\n29. Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 3 months after final dosing.\n30. Participants of childbearing potential who are pregnant, breastfeeding or planning to conceive. This is an FDA requirement.","21 Years","65 Years",{"count":163,"type":22},30,[165],"PHASE2","The goal of this study is to learn how psilocybin delivered with mindfulness-based therapy may help symptoms of posttraumatic stress disorder (PTSD). This is an assessor-blinded, randomized, controlled study in participants with PTSD. The study will investigate the changes in brain activity, connectivity, and microstructural neuroplasticity assessed using EEG\u002FEMG and multimodal MRI measures after administration of one oral dose of psilocybin, accompanied either with standard \"psychological support\" only; or with standard support plus Mindfulness-based Cognitive Therapy (MBCT).",[168,30],"Post Traumatic Stress Disorder",[36,170,171,41,172],"functional MRI","Mindfulness-based Cognitive Therapy","microstructural neuroplasticity",{"date":126,"type":47},{"date":175,"type":22},"2026-07-01",{"date":177,"type":22},"2029-12",{"name":179,"class":84},"Anthony P King",{"id":181,"slug":4,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":187,"sex":17,"minAge":18,"maxAge":92,"enrollmentInfo":188,"targetDuration":4,"studyType":23,"phases":190,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":85},"100644284","NCT07664540","Fasting, Exercise, and Diet to Activate Autophagy in Depression","Targeting Autophagy in Depression: Fasting, Exercise, Diet","AutoFast","Inclusion Criteria:\n\n* age: 18-40 years\n* BMI: between 18.5 and 24.9 kg\u002Fm2 (SG1\u002F2) or BMI between 25.0 and 39.9 kg\u002Fm2 (SG3\u002F4)\n* ability to understand the study procedure and give consent\n* Written informed consent\n* SG1 women: any fitness level\n* SG2 men: VO2max \\\u003C 45 ml\u002Fkg\u002FKG29,30\n* Available to conduct CPET on menstrual cycle days 1-5 (SG1\u002F3)\n* No infection with HIV or Hepatitis B\u002FC\n\nExclusion Criteria:\n\n* No infectious illness for at least two weeks prior to the test\n* No vitamin supplementation during the week prior to the performance test\n* SG3 and SG4: More than 1 hour moderate exercise per week\n* No use of hormonal contraceptives in the last 6 months before the onset of the study (SG1\u002F3)\n* a clinically diagnosed menstrual disorder (e.g., polycystic ovarian syndrome or amenorrhea) (SG1\u002F3)\n* having given birth within the 12 months before inclusion in the study (SG1\u002F3)\n* pregnancy or breastfeeding (SG1\u002F3)\n* premenstrual dysphoric disorder (PMDD) (SG1\u002F3)\n* history of epileptic seizure\n* history of depression\n* history of manic or psychotic episode\n* existing\u002Fcurrent eating disorders (bulimia nervosa, anorexia nervosa) within the past 5 years\n* inability to communicate adequately in speech\n* inability to follow instructions\n* regular use of medication other than thyroxine\n* alcohol consumption as equivalent doses of more than 12 g of pure alcohol per day on average for women and 24 g of pure alcohol per day for men\n* vegan diet\n* daily nicotine consumption\n* currently or history of (regular) consumption of illegal drugs within the last year\n* known diseases of the cardiovascular system\n* arterial hypertension above 160\u002F90 mmHg at rest\n* known pulmonary diseases\n* arthritis and rheumatic diseases and conditions\n* hematologic diseases\n* bronchial asthma\n* surgery less than 4-6 months ago\n* orthopedic or other diseases (e.g. neurological) that preclude maximum load on the bicycle ergometer\n* anemia (\\\u003C12.0 g\u002Fdl for women and \\\u003C14.0 g\u002Fdl for men)",true,{"count":189,"type":22},120,[65],"Depression is a common mental health condition that affects millions of people worldwide and is a leading cause of disability. Although current treatments can be effective, many patients do not fully recover or experience long-term improvement. This study aims to better understand how lifestyle factors such as physical activity and diet-related processes may influence biological mechanisms that could be linked to depression.\n\nThe study focuses on a natural cellular process called autophagy, which helps cells remove damaged components and maintain healthy function. Autophagy is influenced by energy availability in the body and may be affected by behaviors such as physical exercise and caloric restriction. Early evidence suggests that changes in autophagy may also be linked to mood regulation and depression, but this relationship is not yet well understood in humans.\n\nIn this exploratory study, we will investigate how physical activity influences autophagy and related metabolic and molecular processes in healthy adults. We will also examine whether these effects differ between individuals with different body weight and fitness levels, and between women and men.\n\nA total of approximately 120 healthy adults aged 18 to 40 years will participate. Participants will be divided into four groups based on sex and body weight (normal weight or overweight). Each participant will attend study visits at the University Hospital Zurich and perform a standardized cycling exercise test under medical supervision.\n\nDuring the exercise test, participants will perform a graded cycling protocol that gradually increases in intensity until exhaustion. We will collect small blood samples from a vein and from a fingertip at several time points before, during, and after exercise. Saliva samples will also be collected to measure stress-related hormones. Additional measurements include heart rate, breathing parameters, oxygen consumption, and physical performance.\n\nBlood and saliva samples will be analyzed using advanced laboratory techniques to study changes in metabolism, immune signaling, hormones, gene activity, and markers related to autophagy. These analyses will help identify biological pathways that are activated by exercise and may be relevant to brain health and depression.\n\nParticipants will undergo medical screening before inclusion to ensure safety. Individuals with certain medical conditions or factors that could interfere with the study results will not be included. Participation is voluntary, and participants may withdraw at any time without consequences.\n\nThe study involves minimal risks associated with blood sampling and intense physical exercise, which will be performed under close medical supervision. The expected benefit is improved scientific understanding of how lifestyle-related biological processes may be linked to mental health, which could support the development of new preventive or therapeutic strategies for depression in the future.",[30,193],"Overweight (BMI > 25)",[195,196,197,198,199,200,201,202],"autophagy","multi-omics","depression","steroid hormones","autophagy flux","performance testing","metabolomics","proteomics","2026-06-17",{"date":148,"type":47},{"date":206,"type":22},"2026-09-11",{"date":208,"type":22},"2029-09-30",{"name":210,"class":84},"University of Zurich",{"id":212,"slug":4,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":220,"conditions":221,"keywords":225,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":85},"100614420","NCT07279363","Deaf CBT-TS to Reduce Suicide Risk","Cognitive Behavioral Therapy for Treatment-Seeking to Improve Treatment Engagement and Reduce Suicide Risk Among Deaf Individuals","Inclusion criteria:\n\n* adult (aged 18 years or older)\n* Self-identify as Deaf or hard of hearing (any degree of hearing loss)\n* Primary method of communication is American Sign Language\n* Positive screen for one or more mental health disorders including depression (PHQ-9 \\> 10), anxiety (GAD-7 \\> 10), posttraumatic stress disorder (PCL-5 \\> 31), insomnia (ISI \\> 15), or alcohol use disorder (AUDIT \\> 16)\n* No current professional mental health or alcohol specialty treatment (e.g., counseling, psychiatric services) per standardized self-report\n* Access to video chat technology with internet and webcam.\n\nExclusion criteria:\n\n* unable to communicate with the researcher in American Sign Language\n* current alcohol withdrawal necessitating medical evaluation\n* current psychiatric impairment necessitating emergency services or inpatient admission (i.e., imminent danger of harm to self or others)\n* unable to comprehend the nature of the study",{"count":218,"type":22},110,[65],"The goal of this clinical trial is to learn if a short, Zoom-based intervention, Cognitive Behavioral Therapy for Treatment-Seeking for Deaf Individuals (Deaf CBT-TS) can change beliefs about mental health treatment and increase treatment-seeking behaviors in Deaf adults with untreated mental health or alcohol use problems. It will also see if Deaf CBT-TS may reduce suicide risk and explore factors that may increase the effectiveness of Deaf CBT-TS. The main questions it aims to answer are:\n\n* Does Deaf CBT-TS increase positive beliefs about treatment and increase treatment-seeking behaviors?\n* Does Deaf CBT-TS increase hope and reduce mental health symptoms, suicide ideation, and alcohol use?\n* Is Deaf CBT-TS more effective for individuals with less cultural stress compared to those with high levels of cultural stress?\n* Is Deaf CBT-TS more effective for Deaf individuals in residential areas with more Deaf resources than those with less Deaf resources? Researchers will compare individuals who complete Deaf CBT-TS to those on a waitlist to see if Deaf CBT-TS works to increase positive beliefs about treatment and treatment-seeking behaviors.\n\nParticipants will:\n\n* Complete a baseline assessment including demographic information, measures of hope, general mental health and functioning, alcohol use, suicide ideation, cultural stress, and beliefs about treatment.\n* Receive Deaf CBT-TS (2 sessions) or be placed on a waitlist with the option of receiving Deaf CBT-Ts after 4 months\n* Complete two follow-up assessments in 2 and 4 months.",[30,68,222,145,223,224],"PTSD - Post Traumatic Stress Disorder","Alcohol Use Disorder (AUD)","Suicide Ideation",[226,227,228,229,230],"Deaf","Mental Health","Treatment-Seeking","Suicide","Cognitive Behavioral Therapy for Treatment-Seeking",{"date":232,"type":47},"2026-06-22",{"date":234,"type":22},"2026-09",{"date":236,"type":22},"2029-05",{"name":238,"class":84},"University of Rochester",{"id":240,"slug":4,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":187,"sex":17,"minAge":160,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":23,"phases":247,"briefSummary":248,"conditions":249,"keywords":250,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":261,"leadSponsor":262,"locationsCount":85},"100641757","NCT07651293","Using Fenfluramine to Test the Serotonin Deficiency Theory of Depression","FenDep","Inclusion Criteria for All Participants:\n\n* Aged 21 years and over.\n* Able to lie comfortably on their back for scanning.\n* Participants must agree to use one of the contraception methods listed in Appendix 1.\n* Capable of providing written informed consent and willing to comply with the requirements and restrictions listed in the consent form.\n* Able to read, comprehend, and record information written in English.\n* Able to access the internet through their own electronic device.\n\nInclusion Criteria for Participants with Major Depressive Disorder (MDD):\n\n* Major depressive episode diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as moderate to severe.\n* Scoring above 20 on the Montgomery-Åsberg Depression Rating Scale (MADRS).\n* Have never taken antidepressants, or are currently unmedicated for at least 8 weeks before signing the informed consent form.\n* Not classified as treatment-resistant.\n* Ongoing relationship with a general practitioner (GP) or other healthcare professional.\n\nInclusion Criteria for Healthy Controls:\n\n\\- Healthy as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, and laboratory tests.\n\nExclusion Criteria for All Participants:\n\n* Presence of a general medical or psychiatric condition (excluding MDD in the relevant population), as revealed by a physical and psychiatric examination, which, in the opinion of the Principal Investigator (PI), would impair the safety of the participant or the scientific integrity of the study.\n* Ongoing treatment with medication that, in the opinion of the investigator, would compromise participant safety or the scientific integrity of the study, including but not limited to compounds known to interact with the serotonin 2A (5-HT2A) receptor or to have a significant effect on the synthesis and\u002For release of serotonin (5-HT).\n* Use of illicit compounds in the 3 months before consent, including but not limited to classic psychedelics, stimulants, 3,4-methylenedioxymethamphetamine (MDMA), and cannabis.\n* Unwillingness or inability to follow the procedures outlined in the protocol.\n* The participant is mentally or legally incapacitated.\n* Contraindications to blood sampling and\u002For arterial cannulation, including but not limited to peripheral vascular disease or Raynaud's phenomenon.\n* Contraindications to the administration of dl-fenfluramine include medications that have a significant effect on the synthesis and\u002For release of 5-HT.\n* Abnormal Allen's test and\u002For prolonged Prothrombin Time (PT), due to the arterial cannulation required for the positron emission tomography (PET) scans.\n* Participation in another research study involving ionising radiation exceeding 10 mSv within the last year.\n* Contraindications to magnetic resonance imaging (MRI) scans include, but are not limited to, pacemakers, recent metallic implants, foreign bodies in the eye, or other contraindications identified by a standard pre-MRI questionnaire.\n* Claustrophobia or any other condition that would render the participant incapable of undergoing MRI\u002FPET scanning.\n* Pregnancy or breastfeeding.\n\nExclusion Criterion for MDD Participants:\n\n\\- History of suicide attempts requiring hospitalisation.\n\nExclusion Criteria for Healthy Controls:\n\n* History of an Axis I psychiatric diagnosis.\n* History of a neurological or general medical illness that, in the opinion of the investigator, would compromise participant safety or the scientific integrity of the study.",{"count":246,"type":22},46,[65],"Clinical depression is a common and disabling condition characterised by persistent low mood and loss of interest that interferes with daily functioning. Serotonin is a key brain neurotransmitter involved in mood regulation, and a leading theory proposes that depression is associated with impaired serotonin function (the serotonin deficiency hypothesis), which underpins the use of selective serotonin reuptake inhibitors (SSRIs) as first-line antidepressant treatments. However, the strength and specificity of the link between serotonin dysfunction and depressive symptoms in humans remains uncertain and requires direct evidence in living human brains.\n\nPositron Emission Tomography (PET) allows in vivo quantification of neurotransmitter receptor systems using a radioactive tracer that binds to specific brain targets. The serotonin 2A receptor (5-HT2A) agonist tracer \\[11C\\]Cimbi-36 enables measurement of the active-state 5-HT2A receptor, which is highly expressed in cortical regions implicated in mood regulation. When combined with a pharmacological challenge that acutely increases serotonin levels, changes in \\[11C\\]Cimbi-36 binding can be used to estimate serotonin release capacity across different brain regions.\n\nPrevious work using an amphetamine challenge with \\[11C\\]Cimbi-36 has shown reduced serotonin release capacity in the frontal cortex of patients with depression compared with healthy controls, providing preliminary support for the serotonin deficiency hypothesis. However, amphetamine releases multiple neurotransmitters in addition to serotonin, limiting the ability to attribute these effects specifically to serotonergic dysfunction. Dl-fenfluramine is a more selective serotonin-releasing agent and therefore offers a targeted approach to probe serotonin release in the human brain.\n\nThis case-control observational study will compare serotonin release capacity between unmedicated adults with Major Depressive Disorder (MDD) and healthy control participants using dl-fenfluramine challenge combined with \\[11C\\]Cimbi-36 PET imaging. The primary objective is to test whether individuals with MDD show reduced fenfluramine-induced serotonin release, indexed by changes in \\[11C\\]Cimbi-36 binding, relative to healthy controls. Secondary objectives include exploring how multimodal imaging, blood biomarkers, and behavioural measures relate to serotonin release capacity and depressive symptom severity.\n\nFollowing completion of imaging, participants with MDD who will start SSRI treatment as part of their usual clinical care will be followed for 8 weeks with remote assessments. The study will examine whether baseline measures of serotonin release capacity predict subsequent clinical response to SSRIs, defined primarily by change in clinician-rated depression scores over the treatment period. Together, these data aim to provide a more precise test of the serotonin deficiency hypothesis of depression and to identify potential biomarkers of SSRI treatment response in MDD.",[30],[37,251,252,253,254,255,256],"Serotonin","PET","Fenfluramine","[11C]Cimbi-36","SSRI","Serotonin Deficiency Theory of Depression","2026-06-12",{"date":259,"type":47},"2026-06-16",{"date":175,"type":22},{"date":131,"type":22},{"name":263,"class":84},"Imperial College Healthcare NHS Trust",{"id":265,"slug":4,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":23,"phases":273,"briefSummary":274,"conditions":275,"keywords":276,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":283,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":4},"100641653","NCT07631247","iPath for CP Pilot","Improving Screening and Access to Treatment for Depression in Care Partners of People Living With Dementia","care partners","Inclusion Criteria:\n\n* For 2 Week iPath\\*CP Pilot:\n\n  1. Adults (≥18 years)\n  2. Care partners of persons with dementia who score ≥5 on the PHQ-8 AND PHQ-9 screen\n  3. Can communicate in English\n  4. Have access to an Android based or Apple iOS based phone or tablet capable of running the iPath application.\n\nFor Debrief Interviews:\n\n* Care partners: Interviews will be conducted with a purposeful sample of 6 patients already consented into the study at the completion of T1 data collection, ensuring representation by sex (male\u002Ffemale), perceived usability (low\u002Fhigh) of iPath\\*CP and race\u002Fethnicity.\n* Clinicians: Interviews will be conducted with clinicians and clinical staff who had patients involved in the project.\n\nExclusion Criteria:\n\n* Care partners with:\n\n  1. PHQ-8 score \\\u003C5\n  2. Answering positively for question 9 of the PHQ-9 who also screen positive for suicidal ideation with method, intent, plan or a recent prior suicide\u002Fself-harm attempt, as determined by a positive endorsement of items 3, 4, 5 or 6b (\"Past 3 Months\") on the Columbia-Suicide Severity Rating Scale (C-SSRS) and determined by Dr. Mistler, Psychiatrist at DH, not to be eligible.\n  3. With bipolar disorder or psychosis (documented in the electronic medical record \\[EMR\\])\n  4. With significant cognitive impairment (documented in the EMR or self-reported during eligibility screening)\n  5. With no access to an Android or Apple device\n\nFor Debrief Interviews:\n\n* Patients: Participants withdrawn from the 2 Week iPath\\*CP Pilot.\n* Clinicians: None.",{"count":272,"type":22},15,[65],"Depression is a significant problem in care partners of people living with dementia; despite the expansion of options for accessing evidence-based treatments, most care partners of people living with dementia are not screened for depression and do not receive treatment. The objective of this project is to identify a screening method for depression that is feasible and acceptable to care partners and to adapt an innovative pathway to online evidence-based treatment for depression (iPath\\*D) as a means of increasing mental health literacy, screening rates and treatment access for care partners of people living with dementia. The results are expected to have a major positive impact by providing proof-of-principle for the use of an online pathway to evidence based treatment with the potential for reaching an unprecedented number of care partners who have unmet mental health needs.",[30],[197,277,278,279,280,281,282],"caregiver","AD\u002FADRD","Alzheimer's disease","dementia","care partner","app",{"date":259,"type":47},{"date":285,"type":22},"2026-06",{"date":287,"type":22},"2027-02",{"name":289,"class":84},"Dartmouth-Hitchcock Medical Center",{"id":291,"slug":4,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":161,"enrollmentInfo":295,"targetDuration":4,"studyType":23,"phases":297,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":300,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":85},"100630421","NCT07487454","Sham-Controlled Rapid-Acting Neuromodulation for Depression","Inclusion Criteria:\n\n* English speaking\n* Able to provide informed consent\n* 18-65 years old\n* Meets MDD criteria per the Mini International Neuropsychiatric Interview (MINI)\n\nExclusion Criteria:\n\n* Unable to consent (due to medical condition, acute psychosis, substance use, etc)\n* Use of benzodiazepines or medications that would interfere with TMS treatment as per PI discretion\n* Active substance use or severe substance use that in the opinion of the PI would interfere with study participation\n* Untreated, active psychosis\n* Female patient who is breastfeeding, pregnant or who is planning a pregnancy during the study\n* Contraindications to receiving TMS and\u002For MRI as determined by screening questionnaires\n* Participation in any clinical study with exposure to any investigational treatment or product within the previous 30 days, or plan on concurrent participation in other studies.",{"count":296,"type":22},264,[65],"The goal of this study is to learn whether 5 days of accelerated intermittent theta burst stimulation (iTBS), a rapid form of transcranial magnetic stimulation (TMS), which is a non-invasive procedure that uses magnetic fields to stimulate brain activity, works to treat depression in adults.\n\nThe main questions it aims to answer are:\n\n* Does accelerated iTBS reduce depressive symptoms compared to sham (placebo) stimulation?\n* Are there measurable brain, biological, and digitally measured emotion changes associated with treatment response?\n\nParticipants will:\n\n* Be randomly assigned to receive either active iTBS or sham stimulation\n* Receive 10 stimulation sessions per day for 5 consecutive days (total of 50 sessions)\n* Complete MRI brain scans and EEG recordings before and after treatment\n* Provide blood and saliva samples to measure biological markers\n* Complete depression rating scales and questionnaires at baseline, during treatment, and at follow-up visits\n* Use a secure mobile app to record brief facial and vocal samples during the 5-day treatment and at follow-up visits\n* Return for follow-up visits at 1 week and at 1, 3, 6, and 12 months after treatment",[30],{"date":259,"type":47},{"date":302,"type":22},"2026-12",{"date":304,"type":22},"2028-05",{"name":306,"class":84},"University of California, Davis",{"id":308,"slug":4,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":93,"enrollmentInfo":314,"targetDuration":4,"studyType":23,"phases":316,"briefSummary":317,"conditions":318,"keywords":321,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":328,"leadSponsor":330,"locationsCount":85},"100642658","NCT07642882","Analgesic Efficacy of Multisite rTMS in Fibromyalgia Patients","Analgesic Efficacy of Multisite rTMS in Depressed and Nondepressed Patients With Fibromyalgia and Prediction of the Response: a Double-Blind Randomized Sham-Controlled Study.","MultiStimFM","Inclusion Criteria:\n\n* Chronic pain lasting at least 6 months, with or without associated depressive symptoms;\n* Fibromyalgia (2016 revised ACR criteria and a FIRST questionnaire score of at least 5 out of 6);\n* Average pain intensity ≥ 4\u002F10 on a 0-10 numeric rating scale;\n* Pain present daily or almost daily (≥ 4 days per week);\n* Patients aged over 18 and under 80 years;\n* Patients who have provided written informed consent;\n* Patients whose analgesic treatment has been stable for at least 1 month prior to inclusion and will not need to be modified during the study;\n* Patients who can be followed for the duration of the study (10 weeks);\n* Patients covered by a health insurance plan or otherwise eligible.\n\nExclusion Criteria:\n\n* Ongoing litigation;\n* Contraindication to rTMS:\n* Implanted electronic devices and\u002For conductive objects near the coil: Patients with an active implanted device that is activated or controlled by physiological signals (e.g., pacemakers, implantable cardiac defibrillators \\[ICD\\], vagus nerve stimulators \\[VNS\\], wearable cardioverter defibrillators \\[WCD\\], ocular implants, deep brain stimulation systems, drug infusion pumps or ports, intracardiac leads), even if the device has been removed.\n* Non-removable metallic objects near the coil:\\*\\* Patients with a conductive, ferromagnetic, or magnetically sensitive metal implant in the head or within 30 cm of the coil (e.g., cochlear implants, implanted electrodes\u002Fstimulators, aneurysm clips or coils, stents, or bullet fragments);\n* Current abuse of drugs or psychoactive substances, including alcohol (according to DSM-5 criteria);\n* Pregnancy or breastfeeding;\n* Epilepsy or a history of epilepsy;\n* Unstable or progressive medical conditions (e.g., cancer);\n* Psychosis according to DSM-5 criteria;\n* Presence of another pain condition more severe than the one qualifying for inclusion;\n* Failure to correctly complete pain self-assessment diaries between inclusion and randomization (fewer than 4 pain scores recorded over 7 days);\n* Inability to understand the informed consent form, or subjects under legal guardianship or curatorship;\n* Participation in another research protocol within 30 days prior to inclusion.",{"count":315,"type":22},36,[65],"Repetitive Transcranial Magnetic Stimulation (rTMS) of the motor cortex is a recognized analgesic technique for the treatment of fibromyalgia pain, which represents a largely unmet medical need. However, the effectiveness of motor cortex rTMS is inconsistent, being observed in only about 40% of patients and not always long-lasting. It has been previously shown that predictive factors for a lack of response to motor cortex rTMS include the presence of depressive symptoms, and that prefrontal cortex rTMS is not effective for pain, even though this treatment has proven efficacy in major depressive disorder.\n\nThe hypothesis is that targeting both the motor and prefrontal cortices with rTMS will yield a particularly beneficial effect in fibromyalgia patients presenting with comorbid depressive symptoms.\n\nGiven the absence of established biomarkers for predicting rTMS response, an additional aim will be to develop reliable indicators of rTMS efficacy, based on clinical phenotype and measurements of oscillatory patterns assessed by electroencephalogram (EEG) recordings.",[319,30,320],"Fibromyalgia","Chronic Pain",[319,320,123,33,322,323],"Neuromodulation","EEG","2026-06-08",{"date":326,"type":47},"2026-06-11",{"date":234,"type":22},{"date":329,"type":22},"2028-11",{"name":331,"class":84},"Hospital Ambroise Paré Paris",{"id":333,"slug":4,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":338,"enrollmentInfo":339,"targetDuration":4,"studyType":23,"phases":341,"briefSummary":342,"conditions":343,"keywords":345,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":85},"100643449","NCT07620288","Comparing Outcomes of Theta Burst Stimulation in Depression Using Advanced PET Imaging","Measuring Neuroplasticity Outcomes of Theta Burst Stimulation in Depression Using Advanced PET Imaging","Inclusion Criteria\n\nFor inclusion in the study, participants must fulfill all the following criteria:\n\n1. 18 to 55 years old.\n2. Competent to provide voluntary informed consent.\n3. English comprehension and verbal communication (participants must be able to both understand and speak English sufficiently to follow study procedures and be understood by study personnel\n4. Referred by their treating physician.\n5. Mini-International Neuropsychiatric Interview-confirmed diagnosis of MDD, as a single or recurring episode.\n6. Symptoms of MDD have not improved after ≥ 1 adequate antidepressant medication trial in the current depressive episode29.\n7. Baseline score of ≥18 on the 17-item Hamilton Rating Scale for Depression (HRSD-17).\n8. Maintained a stable treatment regimen for at least four weeks prior to entering the study, defined as being on a stable antidepressant regimen, a stable psychotherapy regimen, both, or neither (i.e., no treatment), with no changes during this period.\n\nExclusion Criteria\n\nParticipants fulfilling any of the following criteria will be excluded from the study:\n\n1. Any comorbid mental health disorders (including, but not limited to lifetime history of psychotic disorders, OCD, and\u002For bipolar I or II disorder) with the exception of anxiety\u002Fpanic disorders, posttraumatic stress disorder and ADHD\n2. Current or past (\\\u003C 3 months) substance (including nicotine) or alcohol abuse\u002Fdependence, as defined in DSM-5 criteria.\n3. Positive urine test for illegal substances, cannabis, or cotinine.\n4. Significant unstable medical or neurologic illness confirmed by medical history (e.g. uncontrolled diabetes, or renal dysfunction).\n5. Breastfeeding or pregnant (confirmed via urine test).\n6. BMI \\> 30 or BMI \\\u003C 18.\n7. Contraindication for TMS (e.g., personal history of epilepsy or convulsion, metallic head implant, pacemaker).\n8. Contraindication for MRI (e.g. metallic implant, claustrophobia).\n9. Have received a cumulative radioactivity dose \\> 15.2mSv during the last 12 months.\n10. Have active malignancies (due to high chance of undergoing radiation therapy).\n11. Suicide attempt in the past three months and\u002For active suicidal intent.\n12. Failed (non-response) course of ECT or rTMS treatment in the current depressive episode.\n13. Benzodiazepine or lithium use. Other psychotropic medications (e.g. ADHD medications) are permitted, if stable in the 4 weeks prior to and during the treatment course)\n14. Any other condition that, in the opinion of the investigators, would adversely affect the participant's ability to complete the study.","55 Years",{"count":340,"type":22},20,[65],"The proposed project will investigate the neurobiological mechanisms of accelerated intermittent Theta Burst Stimulation (iTBS) in major depressive disorder (MDD) using an advanced multimodal imaging approach. This single-arm, within-subject study will deliver one week of accelerated iTBS and use pre-\u002Fpost-treatment PET\u002FMRI to quantify changes in synaptic density, functional connectivity, and microstructural integrity. We will combine \\[¹⁸F\\]SynVesT-1 PET with functional, neurochemical and anatomical MRI, such as resting-state fMRI, magnetic resonance spectroscopy (MRS) and neurite orientation dispersion and density imaging (NODDI), to capture treatment-related plasticity. This integrated design will link molecular and network-level mechanisms to clinical improvement, providing an unprecedented mechanistic map of how accelerated iTBS restores brain function in depression.",[33,30,344,28],"Depressive Episode",[252,346,347,123,348],"iTBS","accelerated iTBS","MRI","2026-06-05",{"date":351,"type":47},"2026-06-09",{"date":353,"type":22},"2026-08-01",{"date":355,"type":22},"2028-07-30",{"name":357,"class":84},"The Royal Ottawa Mental Health Centre",{"id":359,"slug":4,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":23,"phases":366,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":369,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":373,"locationsCount":85},"100643413","NCT07636694","Effects of Concurrent and Consecutive Repetitive Transcranial Magnetic Stimulation (rTMS) and Cognitive Bias Modification (CBM)","TMS CBM","Inclusion Criteria:\n\n* Aged 18 years or above\n* Right-handed\n* Normal or corrected hearing and vision\n* Obtained primary education or above\n* Able to fluently read and understand Chinese\n* Beck's Depression Inventory-II (BDI-II) score ranging from 14-28\n\nExclusion Criteria:\n\n* History of severe physical disease, brain organic diseases, and neurological disorders (e.g., dementia, brain injury, stroke, epilepsy, Parkinson's disease)\n* History of substance use\u002F dependence\u002F withdrawal\n* Participants with intellectual disability based on IQ scores\n* Participants with contraindications for rTMS such as foreign metal bodies, implant devices (cochlear implants) or history (personal or family) of seizure\n* Participants who are not suitable to be scanned by magnetic resonance imaging (MRI) machine (e.g., claustrophobic, pregnant, metal in the body, hearing aids)",{"count":365,"type":22},180,[65],"The goal of this study is to learn whether combining repetitive transcranial magnetic stimulation (rTMS) with a computerized behavioral intervention (imagery cognitive bias modification, CBM-I) reduces negative interpretation bias and mild-to-moderate depressive symptoms. The study will also examine neural changes in the dorsolateral prefrontal cortex (DLPFC) and whether timing of interventions affects outcomes.\n\nThe main questions it aims to answer are:\n\nDoes active TMS reduce negative interpretation bias and depressive symptoms more than sham TMS? Is delivering CBM-I concurrently with TMS more effective than delivering it consecutively (separate sessions) at reducing negative bias and depressive symptoms? Do combined rTMS + CBM-I approaches produce greater neural changes and improved cognitive control over self-referential interpretation than controls? Researchers will compare active TMS versus sham TMS, and concurrent versus consecutive delivery of CBM-I, to test effects on negative bias and depressive symptoms.\n\nParticipants will:\n\nReceive either active rTMS or sham TMS targeting the DLPFC Complete imagery CBM-I sessions either concurrently with TMS or in separate (consecutive) sessions Undergo assessments of negative interpretation bias, depressive symptoms, and neural measures before and after the intervention",[30],{"date":351,"type":47},{"date":371,"type":47},"2025-02-24",{"date":131,"type":22},{"name":374,"class":84},"The University of Hong Kong",{"id":376,"slug":4,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":23,"phases":384,"briefSummary":385,"conditions":386,"keywords":387,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":85},"100639942","NCT07611773","EEG Prediction and Clinical Efficacy of tDCS in Major Depression","Clinical Efficacy of tDCS in Major Depression: A Controlled Clinical Trial and Analysis of Electrophysiological Biomarker Predictors","DM-TDCS-PREDIC","Inclusion Criteria:\n\n* Patients aged 18 years or over.\n* Patients diagnosed with Major Depressive Disorder with a current depressive episode, based on the criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (American Psychiatric Association, 2013).\n* Score on the Hamilton Depression Rating Scale (HDRS-17) ≥16 (Hamilton et al., 1960).\n* Patients on a stable prescription of antidepressants\u002Fpharmacological medication and who agree to continue this throughout the study; and\u002For, if undergoing psychotherapy, who have maintained this treatment consistently for at least 6 weeks.\n* Demonstrate the ability to apply home-based tDCS appropriately, either independently or with the help of a carer.\n* Have access to an electronic device with a camera to enable monitoring of the intervention, as well as to contact the participant.\n* Have the ability and willingness to commit to the study team to complete all phases of the study.\n* Volunteer to participate and sign the specific informed consent form for this study.\n\nExclusion Criteria:\n\n* Patients with a current manic episode as determined by the Young Mania Rating Scale (YMRS), or a psychotic episode as defined by the MINI scale.\n* Patients who answer 'yes' to questions 4, 5 or 6 of the Columbia Suicide Severity Rating Scale (C-SSRS), a risk assessment and identification tool.\n* Patients with treatment-resistant depression, defined as an inadequate clinical response to two or more courses of antidepressant treatment at appropriate doses and duration.\n* Any previous hospitalisation for suicidal behaviour.\n* Presenting with current chronic or severe insomnia (\\\u003C 4 hours' sleep per night) or sleep apnoea.\n* Presence of any structural lesion (e.g., any structural neurological condition or more subcortical lesions than would be expected for their age, or having suffered a stroke affecting the stimulated area or connected areas) or any other clinically significant abnormality that may affect safety, participation in the study, or confound the interpretation of study results, as determined by the investigator.\n* History or presence of any other condition or comorbidity associated with TDM: cardiac or neurological conditions, cognitive impairment.\n* History of or current diagnosis of any other mental disorder: obsessive-compulsive disorder, bipolar disorder (type 1 or 2), anxiety disorder, agoraphobia, eating disorders, personality disorders.\n* Any exclusion criteria other than those established by clinical guidelines on non-invasive brain stimulation (Woods et al., 2016):\n* Metal implants or head injuries, any electronic devices such as cochlear implants or cardiac pacemakers\n* Brain stimulation within the last 6 months.\n* Clinical or family history of epilepsy or seizure episodes.\n* Presence of dermatological problems (allergic skin reaction at the electrode site, psoriasis, etc.)\n* History of drug or alcohol abuse during the study or in the 3 months prior (with the exception of nicotine).\n* Pending trial or litigation during the course of the trial.\n* Pregnancy.",{"count":383,"type":22},270,[65],"The purpose of this randomized controlled trial is to investigate the non-inferiority, and possible superiority, of a high-dose home-based tDCS protocol compared with a conventional home-based protocol, and to assess its cost-effectiveness, in patients with major depression.\n\nAs a secondary aim, we aim to assess the predictive value of baseline EEG for clinical response to high-dose home-based tDCS treatment in patients with major depression.",[30],[388,389,323,390],"tDCS","Major depression","Cost-effectiveness","2026-06-03",{"date":349,"type":47},{"date":394,"type":22},"2026-06-01",{"date":396,"type":22},"2028-12-31",{"name":398,"class":54},"Ionclinics & Deionic SL",{"id":400,"slug":4,"hasResults":11,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":23,"phases":407,"briefSummary":408,"conditions":409,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":85},"100583633","NCT06878859","Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use","AMP-C: A Digital Therapeutic for Reward Dysfunction in Co-Occurring Depression and Cannabis Use","Inclusion Criteria:\n\n* Aged ≥ 18 years\n* Resides in the United States\n* Able to read and understand English and willing to provide informed consent\u002Fcomply with the study protocol\n* Moderate depressive symptom severity, as indicated by the Patient Health Questionnaire-9 (PHQ-9)\n* Problematic cannabis use, as indicated by the Cannabis Use Disorder Identification Test - Revised (CUDIT-R)\n* Current elevated anhedonia, as indicated by the PHQ-9\n* Interest in receiving treatment for their cannabis use and depression\n* Meet criteria for current MDD and CUD per the DSM-5\n\nExclusion Criteria:\n\n* History of a psychotic disorder or bipolar disorder type I\u002FII\n* Active suicidal ideation or intent based on the Columbia-Suicide Severity Rating Scale\n* Current psychotherapy engagement\n* Changes in psychotropic medication within six weeks of the start of study",{"count":406,"type":22},80,[65],"The purpose of this study is to examine the feasibility, acceptability, and preliminary efficacy of a digital intervention for co-occurring cannabis use and depression. Participants will be randomized to complete Amplification of Positivity - Cannabis Use (AMP-C) or symptom tracking. The main outcomes will include changes in depressive symptoms and cannabis use, as well as usability ratings.",[30,410,411],"Cannabis Use Disorder","Mental Disorder",{"date":413,"type":47},"2026-06-02",{"date":415,"type":47},"2026-02-23",{"date":417,"type":22},"2029-06-29",{"name":419,"class":84},"Massachusetts General Hospital",{"id":421,"slug":4,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":23,"phases":429,"briefSummary":430,"conditions":431,"keywords":440,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":85},"100640612","NCT07619092","Flumazenil for Benzodiazepine Reversal in Electroconvulsive Therapy","Flumazenil for Benzodiazepine Reversal in Electroconvulsive Therapy (FLEET): A Randomized Controlled Trial","FLEET","Inclusion criteria:\n\n* Current depressive episode (unipolar or bipolar), corresponding to ICD-10 codes F31.3-5, F32 or F33.\n* Admitted at a study affiliated department in the Mental Health Services of the Capital Region of Denmark\n* Referred to ECT by the regular psychiatrist and has given consent to ECT\n* Currently receiving treatment with a benzodiazepine and\u002For zopiclone, at a minimum daily dose equivalent to 0.5 mg lorazepam.\n\nExclusion criteria:\n\n* Involuntary treatment with ECT\n* Known gross abnormalities in brain structure deemed likely to influence cognitive functioning\n* Pregnancy or breast-feeding\n* Inability to read or understand Danish\n* Acute organic brain disease (e.g., delirium) influencing the ability to give informed consent\n* Any pre-existing condition associated with an increased risk of prolonged or uncontrollable seizures, including but not limited to epilepsy or alcohol- or benzodiazepine withdrawal states\n* Conditions associated with reduced metabolism of flumazenil (e.g., liver failure)",{"count":428,"type":22},145,[65],"The goal of this study is to investigate whether administering flumazenil to reverse the effects of benzodiazepines and\u002For zopiclone during electroconvulsive therapy (ECT) can help reduce cognitive side effects without diminishing treatment effectiveness in hospitalized patients with depression.\n\nThe investigators hypothesize that blockade of the GABA receptor with flumazenil will reduce cognitive side effects through improved seizures and a reduced need for electrical charge escalation during the ECT series. Cognitive side effects will be measured by the total score on the Screening for Cognitive Impairment in Psychiatry (SCIP) (primary outcome) at follow-up after completion of the ECT series. Furthermore, it is expected that the flumazenil strategy will reduce pre-treatment anxiety and improve patient satisfaction (secondary outcomes). In addition, flumazenil strategy is hypothesized to have beneficial effects on subjective cognitive complaints, autobiographical memory, and executive functioning (secondary outcomes). Finally, the flumazenil strategy is expected to be associated with more favorable structural and functional changes in executive functioning and memory-related brain networks after completion of the ECT series, which may, in turn, be linked to better overall cognition and autobiographical memory (secondary outcome measures). For exploratory purposes, the study will also examine longitudinal changes in depressive symptoms and cognitive outcomes from baseline to follow-up (tertiary outcomes).\n\nInvestigators will compare two different pre-ECT benzodiazepine management strategies:\n\n1. Flumazenil strategy (experimental): continued benzodiazepine and\u002For zopiclone use up until the time of the ECT session, followed by administration of flumazenil immediately prior to ECT\n2. Benzodiazepine withholding strategy (treatment as usual):\n\ndiscontinuation of benzodiazepines and\u002For zopiclone prior to the ECT in accordance with standard clinical practice",[30,432,433,434,435,436,437,438,439],"Bipolar Disorder (BD)","Functional Magnetic Resonance Imaging (fMRI)","Cognition","Autobiographical Memory","Electroconvulsive Therapy","ECT","Treatment Outcome","Inpatients",[441,442,443,444,445,446,439,37,447,438,434],"flumazenil","benzodiazepine reversal","electroconvulsive therapy","randomized controlled trial","functional magnetic resonance imaging","Autobiographical Memory Test (AMT)","Bipolar Disorder","2026-05-27",{"date":394,"type":47},{"date":451,"type":47},"2026-01-15",{"date":453,"type":22},"2028-08",{"name":455,"class":84},"Anders Jørgensen",{"id":457,"slug":4,"hasResults":11,"nctId":458,"briefTitle":459,"officialTitle":459,"acronym":460,"eligibilityCriteria":461,"healthyVolunteers":11,"sex":17,"minAge":462,"maxAge":463,"enrollmentInfo":464,"targetDuration":4,"studyType":23,"phases":466,"briefSummary":467,"conditions":468,"keywords":471,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":481,"locationsCount":484},"100639687","NCT07617467","Group-based ACT for Psychological Distress of Young People","ACT-YOUNG","Inclusion Criteria:\n\n* Score on DASS-21 depression scale ≤ 14\n\nExclusion Criteria:\n\n* Psychosis","16 Years","25 Years",{"count":465,"type":22},212,[65],"This clinical study investigates the effectiveness of two psychological treatment formats for young people aged 16-25 with symptoms of depression, anxiety, stress, or interpersonal difficulties. The study compares group-based Acceptance and Commitment Therapy (ACT) with treatment as usual (TAU), most frequent that would be individual psychotherapy, both of which are established treatment approaches.\n\nThe study uses a randomized controlled design (RCT), in which participants are randomly assigned to one of the two treatment conditions. This allows for a systematic comparison of treatment outcomes between ACT delivered in a group format and standard individual therapy.\n\nThe ACT group intervention consists of a structured program in which participants meet regularly over a defined treatment period. The treatment focuses on processes such as psychological flexibility, acceptance of internal experiences, and engagement in actions aligned with personal values.\n\nThe individual therapy condition consists of one-to-one sessions with a clinician, following standard therapeutic practice. Treatment content and duration are tailored to the participant's clinical presentation and therapeutic needs.\n\nOutcome measures include standardized assessments of mental health symptoms, functioning, and psychological processes. These assessments are conducted at baseline, during the treatment period, at post-treatment, and at follow-up time points. Data collected from these measures will be used to evaluate changes over time and differences between the two treatment conditions.\n\nThe primary aim of the study is to determine whether group-based ACT is as effective as, or more effective than, individual psychotherapy for young people receiving mental health services. The results are expected to contribute to improved knowledge about treatment options for this age group and inform future clinical practice.",[30,469,68,470],"Depression Anxiety Disorder","Anxiety Depression",[197,472,473,474,475],"Acceptance and Commitment Therapy","anxiety","anxiety depression","adolescents","2026-05-22",{"date":394,"type":47},{"date":479,"type":47},"2026-03-09",{"date":396,"type":22},{"name":482,"class":483},"Sorlandet Hospital HF","OTHER_GOV",2,{"id":486,"slug":4,"hasResults":11,"nctId":487,"briefTitle":488,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":11,"sex":17,"minAge":490,"maxAge":18,"enrollmentInfo":491,"targetDuration":4,"studyType":23,"phases":493,"briefSummary":494,"conditions":495,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":85},"100607198","NCT07185438","Feasibility, Safety, and Preliminary Clinical Efficacy of Magnetic Resonance Imaging-guided Repetitive Transcranial Magnetic Stimulation (rTMS) in Adolescents With Depression: A Randomized, Double-Blind, Controlled Pilot Study","Inclusion Criteria:\n\n1. Age 12 - 18\n2. Diagnosis of major depressive disorder (MDD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed through the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime version (K-SADS-PL), currently in a depressive episode\n3. Score≥40 on the CDRS-R\n4. Stable pharmacological treatment: At least 4 weeks of stable psychiatric medication use prior to enrollment, with continuation of the same psychiatric medication regimen throughout the study.\n\nExclusion Criteria:\n\n1. Psychiatric comorbidities other than anxiety disorders\n2. Depression with psychotic symptoms\n3. Young Mania Rating Scale (YMRS) score \\>13\n4. A history of neurological disorders (e.g., epilepsy, brain injury) or severe somatic diseases (e.g., thyroid disorders, lupus, diabetes, pulmonary, hepatic, or renal impairment, major trauma)\n5. Patients currently using anticonvulsants or high-dose benzodiazepines\n6. A history of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), or other neuromodulation treatments\n7. A history of alcohol or substance abuse or dependence\n8. Women who are pregnant or breastfeeding\n9. Current high suicide risk\n10. Potential complicating factors related to transcranial magnetic stimulation, such as scalp conditions or perforations that may affect magnetic field delivery\n11. Contraindications to MRI","12 Years",{"count":492,"type":22},45,[65],"This study aims to assess the feasibility, safety, acceptability, and preliminary efficacy trends of a Magnetic Resonance Imaging-guided Repetitive Transcranial Magnetic Stimulation (rTMS) intervention for adolescent depression through a pilot clinical trial. The findings will inform the design and optimization of subsequent formal randomized controlled trials, providing essential evidence for their execution.",[30],"2026-05-20",{"date":498,"type":47},"2026-05-26",{"date":500,"type":47},"2025-09-15",{"date":502,"type":22},"2027-12-30",{"name":504,"class":84},"First Affiliated Hospital of Chongqing Medical University",{"id":506,"slug":4,"hasResults":11,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":510,"eligibilityCriteria":511,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":161,"enrollmentInfo":512,"targetDuration":4,"studyType":23,"phases":514,"briefSummary":515,"conditions":516,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":85},"100594665","NCT07022405","Stratified Pharmacological Approaches for Regulating Circuit-Level Effects","Stratified Pharmacological Approaches for Regulating Circuit-Level Effects Study","SPARCLE","Inclusion Criteria:\n\n* 18-65 years old (inclusive)\n* Fluent and literate in English, with non-impaired intellectual abilities to ensure adequate comprehension of the task instructions.\n* Willing to provide written, informed consent.\n* Functional magnetic resonance imaging (fMRI) scanning eligibility. All participants will need to successfully complete the screening forms at the Stanford Center for Cognitive and Neurobiological Imaging (CNI).\n* Patient Health Questionnaire-8 (PHQ-8) \\>\u002F= 10\n* Meet the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) diagnostic criteria for current or recurrent nonpsychotic Major Depressive Disorder (MDD) established by the Mini International Neuropsychiatric Interview (MINI)\n\nExclusion Criteria:\n\n* Suicidality with active plan or as determined clinician judgment\n* Current or lifetime history of medical illness or brain injury that may interfere with assessments as determined by clinician judgment\n* Severe impediment to vision, hearing, and\u002For hand movement likely to interfere with ability to complete the assessments, or is unable and\u002For unlikely to follow the study protocols as determined by clinician judgment\n* Pregnant, breastfeeding or unwilling or unable to use adequate birth control throughout the study\n* History of non-responsive depression to dopamine agonists\n* Any contraindication to being scanned in the 3.0T fMRI scanner, such as a cardiac pacemaker or implanted device that has not been cleared for scanning\n* Previous or current DSM-5 bipolar disorder (I, II, not otherwise specified), schizophrenia spectrum or other psychotic disorders, or psychosis or as determined by clinician judgment\n* Previous or current diagnosis of Attention-Deficit\u002FHyperactivity Disorder (ADHD)\n* Meeting DSM-5 criteria for current Obsessive-Compulsive Disorder (OCD) or eating disorder\n* Meeting DSM-5 criteria for alcohol use disorder or substance use disorder within the last 12 months\n* Clinically significant presence\u002Fhistory of impulsive-compulsive behaviors or control disorder including but not limited to gambling disorder within the last 12 months.\n* Current use or use of psychotropic medication within the past month. (If the participant's usual treating clinician agrees with discontinuing the medication, participants may enroll after tapering off the medication under the supervision of either their usual clinician or the study clinician. A washout period of 5 half-lives-or a different duration as determined by the study clinician-must be completed before the first scan.)\n* Concurrent participation in other intervention or treatment studies",{"count":513,"type":22},60,[165],"This research study aims to understand how people with depression respond to the medication pramipexole and to determine whether clinical response differs depending on the function of specific circuits in the brain. The investigators hope to learn which circuits are involved in depression and how these circuits interact with pramipexole to affect mood, behavior, and cognition.\n\nEligible participants will undergo an 8-week treatment course of pramipexole followed by a 2-week down taper and follow up. The ultimate goal is to offer people experiencing depression a medication that is alternative to ones that may not have worked in the past and to apply the knowledge the investigators gain from investigating the brain circuits involved in depression to help personalize treatment.\n\nThe investigators invite anyone who has recently experienced symptoms of depression to participate. A prior diagnosis of depression is not required.",[30],"2026-05-12",{"date":519,"type":47},"2026-05-15",{"date":521,"type":47},"2026-01-23",{"date":523,"type":22},"2030-08",{"name":525,"class":84},"Stanford University",{"id":527,"slug":4,"hasResults":11,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":187,"sex":17,"minAge":532,"maxAge":533,"enrollmentInfo":534,"targetDuration":4,"studyType":23,"phases":536,"briefSummary":537,"conditions":538,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":85},"100640494","NCT07589088","AI-GF-GNW on Prolonged Grief Reactions","AI-Assisted Grief-Focused Guided Narrative Writing for Subclinical Prolonged Grief Disorder in Bereaved Chinese Adolescents: A Three-Arm Parallel Randomized Controlled Trial.","Inclusion Criteria:\n\n* Junior and senior high school students currently studying in Chinese Mainland, aged 10-19;\n* Between 6 and 60 months prior to the experimental period, experienced the death of a significant family member or close friend or close friend;\n* The total symptom score of PG-13-R is between 20-29 points;\n* Ability to write and understand written guidelines, to use the mobile phone to interact with AI;\n* Consent to participate in the study.\n\nExclusion Criteria:\n\n* Diagnosed or previously diagnosed with mental illness\n* The bereavement time does not meet the time window\n* PG-13-R score is not within the range\n* At present, there is suicidal ideation or recent severe self harm behavior (Reynolds' Suicidal Ideation Questionnaire, SIQ-JR-4\\>0), and a crisis intervention hotline is provided when necessary.\n* Has received other grief counseling or is currently taking psychiatric medication within the past month","10 Years","19 Years",{"count":535,"type":22},126,[65],"Prolonged Grief Disorder (PGD) is a severe, disabling condition characterized by intense yearning and difficulty accepting the reality of loss, which significantly impairs the academic and psychosocial functioning of bereaved adolescents. While Grief-Focused Cognitive Behavioral Therapy (GF-CBT) is effective, its high cost and resource-intensive nature limit its accessibility for adolescents in mainland China. Grief-Focused Guided Narrative Writing (GF-GNW) offers a scalable, low-cost alternative that facilitates memory integration.\n\nFurthermore, integrating Artificial Intelligence (AI) to provide personalized, structured feedback has the potential to simulate therapist functions and enhance intervention efficacy. However, the specific efficacy of AI-assisted feedback in this context remains empirically unvalidated.\n\nThis parallel randomized controlled trial aims to examine the effectiveness of AI-assisted GF-GNW (AI-GF-GNW) in treating Chinese adolescents (aged 10-19) with subclinical PGD, compared to a no-feedback NF-GF-GNW group and a free writing group. Primary outcomes include PGD symptom severity, while secondary outcomes assess depression, anxiety, and daily functioning. We hypothesize that both active intervention arms will significantly alleviate PGD and related symptoms compared to the free writing group, and that the AI-GF-GNW group will demonstrate a significantly greater reduction in symptoms and functional impairment than the NF-GF-GNW group.",[539,540,30,68,541],"Artificial Intelligence (AI)","Prolonged Grief Symptoms","Disabilities","2026-05-09",{"date":519,"type":47},{"date":545,"type":22},"2026-05-25",{"date":547,"type":22},"2027-05",{"name":549,"class":84},"Peking University",{"id":551,"slug":4,"hasResults":11,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":187,"sex":17,"minAge":462,"maxAge":463,"enrollmentInfo":556,"targetDuration":4,"studyType":557,"phases":4,"briefSummary":558,"conditions":559,"keywords":560,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":85},"100638767","NCT07578142","AcceXible Speech-Based Screening for Depression and Anxiety in University Students (UAQ, Mexico)","Validación Del Sistema de Cribaje y de Seguimiento de Accexible Para depresión y Ansiedad en el Entorno Del Alumnado de la Universidad Autónoma de Querétaro","Inclusion Criteria:\n\n* Provision of voluntary written informed consent\n* Age 16-25 years\n* Current enrollment at BUAP\n* Spanish language proficiency\n* Access to a mobile device with internet connectivity\n* Ability to understand and follow basic acceXible usage instructions\n\nExclusion Criteria:\n\n* Refusal to participate\n* Psychomotor agitation\n* Sensory impairment (visual or auditory)\n* Cognitive impairment",{"count":406,"type":22},"OBSERVATIONAL","Major depressive disorder (MDD) and anxiety are increasingly prevalent among university student populations, yet early detection remains reliant on psychometric instruments tied to diagnostic criteria (e.g., PHQ-9, GAD). Emerging evidence suggests that depression affects both the acoustic properties and content of speech, making speech analysis a promising candidate as a digital biomarker for early screening.\n\nThis study evaluates the validity of acceXible, a speech-based machine learning platform, for the detection and monitoring of depression and anxiety in the student population of the Universidad Autónoma de Querétaro, Mexico. AcceXible captures spontaneous speech through open-ended interview tasks and applies automated acoustic and linguistic analysis.\n\nThe primary objective is to evaluate the validity of the acceXible spontaneous speech analysis system for depression and anxiety screening, assessed against the PHQ and GAD scales as reference standards. Secondary objectives include examining associations between speech-derived variables and other study measures, evaluating participant engagement with digital mental health resources, assessing user satisfaction with the platform, and analyzing longitudinal changes in scores across follow-up assessments.",[30,68],[561,197,473,562],"machine learning","speech analysis","2026-05-05",{"date":565,"type":47},"2026-05-11",{"date":567,"type":22},"2026-09-05",{"date":569,"type":22},"2027-09",{"name":571,"class":54},"Accexible",{"id":573,"slug":4,"hasResults":11,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":577,"eligibilityCriteria":578,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":579,"targetDuration":4,"studyType":23,"phases":580,"briefSummary":581,"conditions":582,"keywords":584,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":85},"100640403","NCT07576686","AI-Guided CBT for Depression and Anxiety","The Significance of Artificial Intelligence-Guided Psychotherapy of Depression and Anxiety Disorders","AI-CBT-DA","Inclusion Criteria:\n\nAge 18 years or older Diagnosis of mild depressive disorder and\u002For anxiety disorder confirmed by a structured clinical interview (MINI) Ability to understand and provide informed consent Access to a device capable of using the digital platform (computer, tablet, or smartphone) Willingness to participate in weekly sessions over a 10-week period\n\nExclusion Criteria:\n\nModerate to severe depressive disorder Current or past diagnosis of psychotic disorder Bipolar disorder Substance use disorder or dependence Primary diagnosis of antisocial personality disorder Severe cognitive impairment or inability to use digital tools Acute suicidal risk requiring immediate intervention Concurrent participation in another structured psychotherapy program-",{"count":189,"type":22},[65],"This study aims to evaluate the effectiveness of an artificial intelligence (AI)-guided cognitive behavioral therapy (CBT) program for the treatment of mild depression and anxiety disorders in adults.\n\nDepression and anxiety disorders are among the most common mental health conditions worldwide and are associated with significant individual and societal burden. Despite the availability of effective treatments, access to psychotherapy remains limited due to insufficient resources and long waiting times. Digital mental health interventions, particularly those supported by artificial intelligence, have the potential to increase accessibility and scalability of evidence-based treatments.\n\nIn this controlled clinical trial, participants diagnosed with mild depressive disorder and\u002For anxiety disorders will be assigned to either an experimental group receiving AI-guided CBT or a control group receiving standard psychiatric care. The intervention will be delivered through a digital platform and will consist of structured weekly sessions over a 10-week period.\n\nThe primary objective of the study is to assess changes in symptoms of depression and anxiety. Secondary outcomes include perceived stress, social support, digital therapeutic alliance, and overall clinical improvement.\n\nThe findings of this study are expected to contribute to the understanding of the role of AI in psychotherapy and its potential to improve access to mental health care.",[30,583],"Anxiety Disorders",[585,586,587,33,68,588,589,590,591],"AI-guided psychotherapy","Cognitive Behavioral Therapy","Digital Mental Health","Artificial Intelligence","Digital Therapeutic Alliance","eHealth","Internet-based CBT","2026-05-01",{"date":594,"type":47},"2026-05-08",{"date":596,"type":47},"2026-01-07",{"date":598,"type":22},"2026-06-10",{"name":600,"class":84},"Aleksandra Stojanovic",{"id":602,"slug":4,"hasResults":11,"nctId":603,"briefTitle":604,"officialTitle":605,"acronym":4,"eligibilityCriteria":606,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":607,"targetDuration":4,"studyType":23,"phases":609,"briefSummary":610,"conditions":611,"keywords":614,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":626,"locationsCount":85},"100599780","NCT07088939","Feasibility and Acceptability of an E-learning Dialectical Behavior Therapy Skills Course","Feasibility and Acceptability of a Self-guided Internet-delivered Dialectical Behavior Therapy Intervention for Adults With Mental Health Challenges","Inclusion Criteria:\n\n* Ages 18 years old and up.\n* Reside in Ontario.\n* Fluent in English.\n* Able to provide autonomous informed consent\n* Reports at least mild depression and\u002For anxiety symptoms\n* Not currently receiving any psychotherapy or psychosocial interventions.\n* Have access to the internet\n\nExclusion Criteria:\n\n* Practical (e.g., scheduling), acute psychiatric (e.g., suicidal ideation nearly every day, recent hospitalization for mental health reasons), or medical reasons (e.g., upcoming surgery, medical procedure, head injury).\n* Not meeting one or more of the above inclusion criteria",{"count":608,"type":22},40,[65],"Dialectical behavior therapy (DBT) is a comprehensive, third-wave psychological intervention designed for patients with complex and severe behavioral, emotional, and interpersonal dysfunction. DBT has since been adapted to shorter, briefer, \"skills training\" formats, which have been effective for a number of mild-to-moderate mental health conditions, including depression and anxiety. Moreover, internet-delivered formats of DBT (iDBT) have similarly started to build support for their effectiveness, although there are fewer studies on digital formats. One study found that over 12 weeks, iDBT was deemed acceptable (e.g., 50% of participants were still active after 4 weeks) and there were improvements in multiple symptom domains, such as depression, anxiety, suicidality, functional disability, as well as alcohol and substance dependence.\n\nIn the current study, the investigators will examine the feasibility, acceptability, and potential efficacy of a new iDBT intervention, packaged as an online e-learning skills course, with adult participants. The study is a pilot trial as iDBT has never been tested in this format through formal research. Thus, this pilot study aims to examine whether this course is usable, practical, and potentially useful to others in the future. The investigators will recruit up to 40 individuals with mild-to-moderate depression and anxiety for an 8-week study. Following a phone screen to determine eligibility, participants will complete a baseline session where they will provide consent, complete a brief interview and questionnaires, and register for the e-learning skills course. Over the course of 8 weeks, participants will be exposed to material adapted from a DBT manual in a self-guided manner. Participants will complete follow-up assessments at 4 and 8 weeks.",[30,68,33,612,613],"Stress","Mood Disorders",[615,616,617,618,619],"dialectical behavior therapy","internet interventions","co-developed interventions","feasibility study","digital health","2026-04-30",{"date":622,"type":47},"2026-05-06",{"date":624,"type":47},"2025-07-20",{"date":353,"type":22},{"name":627,"class":84},"University of Windsor",{"id":629,"slug":4,"hasResults":11,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":4,"eligibilityCriteria":633,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":161,"enrollmentInfo":634,"targetDuration":4,"studyType":23,"phases":635,"briefSummary":637,"conditions":638,"keywords":641,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":646,"completionDateStruct":648,"leadSponsor":650,"locationsCount":85},"100585433","NCT06902298","Personalized Ultrasonic Brain Stimulation for Depression (R61)","Personalized Ultrasonic Brain Stimulation for Depression: A Study of Target Engagement and Mood Effects","Inclusion Criteria:\n\n1. Age 18-65, any gender.\n2. Primary diagnosis of DMS-5 major depressive disorder (MINI).\n3. Current moderate-to-severe depressive episode, without psychotic features, lasting at least 2 months (MINI).\n4. Self-rated 16-item Quick Inventory of Depressive Symptomatology (QIDS) total score \\> 10.\n5. History of at least 2 failed trials of evidence-based antidepressant medication and\u002For psychotherapy (at least one trial during the current depressive episode).\n6. Stated willingness to comply with all study procedures and avoid changes to psychiatric treatments (medications, psychotherapy) for the duration of the study.\n7. For participants of reproductive potential: negative pregnancy test or use of highly effective contraception for at least 1 month prior to baseline; agreement to use such a method throughout the study.\n8. Capacity to provide informed consent; provision of a signed and dated consent form\n9. Currently are under the care of a licensed psychiatrist or other mental health care provider, or a licensed addiction medicine specialist and agrees to promptly inform the investigator or the study staff of any change in these providers.\n10. Agrees to allow any and all forms of communication between the investigators\u002Fstudy staff and any healthcare provider who currently provides and\u002For has provided service to the patient\u002Fsubject within at least two years of study enrollment for the purposes of eligibility confirmation or in case of a safety event.\n11. Agrees to provide the name and verifiable contact information (email and mailing addresses, mobile and land-line phone numbers, as applicable) of at least two persons 22 years or older who reside within a 60-minute drive of the patient's residence. Subject agrees that in the event of a safety concern or event during study participation, research staff is at liberty to contact these individuals if the subject does not respond to contact attempts.\n\nExclusion Criteria:\n\n1. History of serious brain injury or other neurologic disorder.\n2. Poorly managed general medical condition.\n3. Pregnant or breast feeding.\n4. Implanted device in the head or neck.\n5. MRI intolerance or contraindication.\n6. Brain stimulation treatment such as ECT, TMS, or VNS (past month).\n7. Recent change in antidepressant treatments (past month).\n8. 8\\. Moderate-High Risk of Suicide according to the Columbia - Suicide Severity Rating Scale (C-SSRS) Screen Version - Recent (answers YES to Question 3 and NO to Question 6 (Moderate risk) or YES to Question 4, 5, or 6 (High risk)) and\u002For in the clinical judgement of the PI or a study psychiatrist\n9. Suicidal behavior (past year).\n10. Serious suicide attempt 33 (lifetime).\n11. Moderate-to-severe substance use disorder (MINI, past 3 months).\n12. Obsessive compulsive disorder, primary diagnosis (MINI, past month).\n13. Posttraumatic stress disorder, primary diagnosis (MINI, past month).\n14. Bipolar-spectrum disorder (MINI, lifetime).\n15. Schizophrenia-spectrum disorder (MINI, lifetime).\n16. Neurocognitive disorder (DSM-5, past year).\n17. Severe personality disorder.\n18. Clinically inappropriate for participation in the study as determined by the study team.",{"count":163,"type":22},[636,165],"PHASE1","This study will evaluate a new form of non-invasive brain stimulation for individuals with depression. Personalized low-intensity transcranial focused ultrasound stimulation will be delivered using a range of stimulation parameters during psychological and physiological monitoring. Individualized optimal targets will be selected using structural MRI and diffusion tractography. Brain target engagement will be evaluated using functional MRI.",[639,30,640],"Major Depressive Episode","Treatment-Resistant Major Depressive Disorder",[642,643],"ultrasonic neuromodulation","low-intensity focused ultrasound","2026-04-29",{"date":592,"type":47},{"date":647,"type":47},"2025-03-10",{"date":649,"type":22},"2026-11",{"name":651,"class":84},"Brian Mickey",""]